Curcumin

TAMPA, Fla., May 30, 2024 /PRNewswire/ -- A new review in the journal Practical Neurology highlights the efficacy of the supplement Petadolex in preventing migraines. The comprehensive review of "Nutraceuticals for Migraine Management" conducted by headache specialists Drs L. Denysenko and D. Kuruvilla details the effectiveness of four widely available supplements commonly used for migraine prevention. Only Petadolex has data to support reducing migraine frequency with "a predictable dose-response relationship." Continue Reading Only Petadolex has data to support reducing migraine frequency with "a predictable dose-response relationship." Post this Petadolex Butterbur Supplement Proven Effective for Migraine Management Petadolex, a patented preparation of the European butterbur plant, was compared to Coenzyme Q10 (CoQ10), Vitamin D, and Curcumin. Petadolex stands out with numerous clinical trials demonstrating its safety and efficacy as well as laboratory studies showing how and why it works. While Petadolex is derived from butterbur, unlike other available or generic butterbur supplements, it is a proprietary liquid extract of the plant which ensures that potentially toxic native butterbur chemicals are eliminated. The resulting supplement, Petadolex, has reliable, safe and effective pharmacology and contains a minimum 15% petasins and isopetasins, the essential active ingredients proven effective in patient studies. Petadolex, the only liquid form of butterbur used in clinical trials, has been shown to work by multiple mechanisms including inhibiting the release of calcitonin gene-related peptide (CGRP). CGRP, the brain chemical which plays a key role in causing migraine symptoms, is blocked or inhibited by the newest category of migraine prevention prescription drugs. Modifying CGRP is also a natural mechanism of Petadolex as well as blocking migraines by acting on select calcium channel pathways to desensitize sensory neurons. Dr. Lex Denysenko, the lead author of the review, notes: "Our review highlights the potential of butterbur liquid extract, particularly Petadolex, in migraine management. The evidence suggests butterbur may offer a valuable therapy for reducing migraine frequency and improving patient outcomes." For clinicians and individuals seeking natural alternatives to prescription drugs, Petadolex holds promise as a natural remedy for migraine prevention. To learn more about Petadolex and the benefits of its butterbur extract, visit . References About Petadolex Petadolex® butterbur supplement, manufactured by Linpharma, provides premium quality and efficacy for your health needs. Produced in Germany, where supplements are held to the same rigorous standards as medications, our products meet stringent safety and ingredient-purity benchmarks surpassing U.S. standards and domestically manufactured supplements. Backed by Weber & Weber, a renowned German OTC company with over 60 years of expertise in pharmaceuticals, herbal extracts, homeopathic products, and dietary supplements, Linpharma proudly represents these exceptional products in the USA and Canada. Learn more at SOURCE Linpharma

Preclinical results show steady decline in pain, increase in red blood cell stability and reduction in inflammatory markers SAN DIEGO, Dec. 11, 2023 /PRNewswire/ -- Vascarta Inc. ("Vascarta") announced new research findings presented at the American Society of Hematology meeting in San Diego show that a novel transdermal preparation of curcumin from Vascarta reduced pain in humanized mice which suffer with the human form of sickle cell disease. As described in a poster*, several features of human sickle cell pain were measured in these humanized sickle cell mice including sensitivity to mechanical stimulus and cold. In cold conditions, the mice experienced significantly less pain after only hours of treatment and this effect continued during the full 21-day testing period. In room temperature conditions, the mice experienced less pain starting 14 days after first treatment. Mice treated with the transdermal curcumin also showed strong evidence of enhanced red blood cell stability including less hemolysis and improved hematocrit, redox balance and energy production. Additionally, both the liver and spleen showed evidence of improved health. Anti-inflammatory activity was demonstrated by a reduction of multiple markers of inflammation including deactivation of activated mast cells, which are significant contributors to chronic pain. Unlike curcumin taken orally, Vascarta's transdermal curcumin** is highly bioavailable; thus, therapeutic efficacy was achieved by applying only one drop to the abdomen every other day. "This transdermal curcumin formulation represents a potentially new safe and easy-to-deploy approach to sickle cell disease that could be used either for prevention or for treatment not only for chronic pain, but also for many of the other clinical consequences stemming from red cell instability," said Professor Kalpna Gupta (University of California – Irvine), principal investigator. Professor Joel Friedman (Albert Einstein College of Medicine and inventor of Vascarta's patented transdermal drug delivery technology) stated that "the positive sickle cell results are consistent with multiple other preclinical studies that have shown therapeutic benefits of transdermal curcumin for pain, inflammation, cytokine storm, endothelial integrity, hypertension, aging and more. We look forward to forming alliances with strategic partners to enable this novel technology to benefit patients suffering from any of several inflammatory diseases. " *"Mechanism-based Targeting of Sickle Cell Pathobiology and Pain with Novel Transdermal Curcumin" ** Formulated with Curcugen® (Dolcas-Biotech, LLC). About Sickle Cell Disease Sickle cell disease is the most common inherited disease that primarily affects African Americans and Hispanics in the United States, with ~50% of affected individuals suffering chronic pain. About Vascarta Vascarta is a startup pharmaceutical company exploring efficient transdermal delivery of pharmaceuticals to address inflammatory and blood diseases. More information regarding Vascarta's existing research or future collaborations can be found at . Poster Authors & Affiliations Yugal Goel1, Mya A. Arellano1, Raghda T. Fouda1, Daniel Kerr2, Sirsendu Jana7, Reina A. Lomeli1, Graham J. Velasco3, Probal Banerjee2, Donovan A. Argueta1, Mihir Gupta4, Richard Prince8, Abdu I, Alayash7, Joel Friedman5,8, Kalpna Gupta1,6 1,6Hematology/Oncology, Department of Medicine, University of California, Irvine, CA; 2Department of Chemistry and Center for Developmental Neuroscience, The College of Staten Island (CUNY), NY; 3Pathology Department, VA Long Beach Healthcare System, Long Beach, CA; 4Department of Neurosurgery, Yale University School of Medicine, New Haven, CT; 5Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY; 6Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN. 7Laboratory of Biochemistry and Vascular Biology, Center for Biologics Evaluation and Research Food and Drug Administration, Silver Spring, MD, 8Vascarta Inc. 4 Chatham Road, 2nd Floor Summit, NJ; 2Department of Chemistry and Center for Developmental Neuroscience, The College of Staten Island, NY. SOURCE Vascarta Inc